Webcast presentation of Simeprevir phase III clinical data

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that Janssen R&D
Ireland and Johnson & Johnson will provide a pre-recorded webcast for investors
and other interested parties on Friday, May 3, at approximately 8:30 a.m.,
Eastern Time (14.30 CET), to discuss simeprevir phase III clinical data
presented at The International Liver Congress of the European Association for
the Study of the Liver (EASL).

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at
www.investor.jnj.com and clicking on “Webcasts/Presentations.”

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR
Mobile: +46 708 537 292

About Simeprevir
Simeprevir is a new generation NS3/4A protease inhibitor jointly developed by
Medivir and Janssen for the treatment of chronic hepatitis C in adult patients
with compensated liver disease. Janssen recently submitted a new drug
application for simeprevir in Japan, the United States and Europe.

For additional information about simeprevir clinical trials, please visit
www.clinicaltrials.gov.

About Hepatitis C
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause
of chronic liver disease and liver transplants, is a rapidly evolving treatment
area with a clear need for innovative treatments. Approximately 150 million
people are infected with hepatitis C worldwide, and 350,000 people per year die
from the disease.

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases.
Medivir has world class expertise in polymerase and protease drug targets and
drug development which has resulted in a strong infectious disease R&D
portfolio. The Company’s key pipeline asset is simeprevir, a novel protease
inhibitor in late phase III clinical development for hepatitis C that is being
developed in collaboration with Janssen R&D Ireland. Medivir has also a broad
product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company’s website:
www.medivir.com

Medivir is a collaborative and agile pharmaceutical company with an R&D focus on
infectious diseases and a leading position in hepatitis C. We are passionate and
uncompromising in our mission to develop and commercialize innovative
pharmaceuticals that improve people’s lives.